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ABSTRACT
Additive manufacturing in tissue engineering has significantly advanced in acceptance and use to address complex problems. However, there
are still limitations to the technologies used and potential challenges that need to be addressed by the community. In this manuscript, we
describe how the field can be advanced not only through the development of new materials and techniques but also through the
standardization of characterization, which in turn may impact the translation potential of the field as it matures. Furthermore, we discuss
how education and outreach could be modified to ensure end-users have a better grasp on the benefits and limitations of 3D printing to aid
in their career development.
VC 2020 Author(s). All article content, except where otherwise noted, is licensed under a Creative Commons Attribution (CC BY) license (http://
creativecommons.org/licenses/by/4.0/). https://doi.org/10.1063/1.5127860
INTRODUCTION
3D bioprinting has rapidly transformed over the past decade
from a niche manufacturing process to a widespread tissue engineer-
ing approach. This technology has advanced the development of tissue
mimetics with clinical potential, paved the way for developing high-
throughput applications for drug discovery, and established tools for
understanding different microenvironments in a controlled fashion.
However, even with these advances, there are limitations to the appli-
cation of these studies to tissues and more complex environments.
Specifically, in this perspective piece, we will discuss the current state
of affairs in 3D printing (3DP) for tissue engineering, its limitations,
and ways in which the field can address these issues. We will focus on
(1) single and multi-material approaches along with decellularized
extracellular matrix (ECM) based bioinks and their broad application
to bioprinting; (2) challenges that need to be addressed for its accep-
tance as a common tool in tissue engineering such as validation
(mechanical, chemical, and bioactivity, etc.) as well as repeatability; (3)
regulatory concerns and potential solutions; and (4) we will conclude
with an insight into how additive manufacturing education could
grow to expedite the adoption of this technology in academic, clinical,
and commercial settings.
CURRENT STATE-OF-THE-ART
For tissue engineering applications, there is a drive to develop
and fabricate tissues or tissue mimetics for use in vitro and in vivo.
Using an additive manufacturing approach, much emphasis has been
placed on systems that are amenable to layer-by-layer construction
that can allow for the fabrication of discrete zones such as the zonal
architecture of cartilage or for complex geometries.1–9 Furthermore,
these tissues and mimetics can only become so large without reaching
limitations in nutrient and waste diffusion. To address this issue, there
has also been an emphasis on manufacturing microvasculature using
3DP10–12 and even incorporating features to enhance vascularization
in vivo.12 These tissue mimetics have also been used to model natural
processes and barriers such as the placental blood barrier, the blood
brain barrier, and the liver.13–16 Importantly, model systems can be
used to understand key aspects of these niches and provide researchers
with a unique point of view that would be unobtainable using tradi-
tional in vivo or in vitro assays. As such, these models will continue to
answer fundamental questions regarding the roles of mechanical cues,
paracrine signaling, growth factor presentation, and cell–cell interac-
tions in an iterative manner only made possible by the spatial and tem-
poral control provided by additive manufacturing.
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However, the driving force behind these major macro-scale tissue
and tissue mimetics is the research into various materials used for
these applications. Some of these materials, such as polycaprolactone
(PCL), poly(lactic-co-glycolic acid) (PLGA), and polystyrene (PS),
have been in use for decades, but how they are being processed and
modified for use under different printing conditions has allowed for
them to evolve with the field.16–18 Furthermore, bioinks, either natu-
rally derived or inspired materials for use with biological samples, are
rapidly evolving to be used in a variety of applications.2,16,19–22 These
materials and their development taken in tandem will help drive and
facilitate advances in the application of 3D printing to answer ques-
tions regarding the key processes in cellular behavior, differentiation,
growth, and development.
The choice of bioink and the printing platform used are closely
intertwined. A number of additive manufacturing techniques such as
extrusion-based, stereolithography, inkjet, and laser-induced forward
transfer (LIFT) are commonly used in additive manufacturing
(Table I).4,22–43 Particularly, there is a high degree of freedom when 3D
printing acellular, single-material constructs with either hydrogels or
thermoplastics. This is because a wide range of temperature, pressure,
and photocrosslinking conditions can be explored using different
printing methods. The printability of biocompatible polymers such as
poly(lactic-co-glycolic acid) (PLGA),34 polycaprolactone (PCL),36,37
polystyrene (PS),44 and polyurethane45 has been extensively character-
ized. Due to the high melting temperatures and viscosity of thermo-
plastics, they are typically extrusion-printed at high temperatures and
pressures. In these cases, the minimum fiber dimensions can be around
a few hundred micrometers as they are limited by the needle size and
material properties. Conversely, conventional electrospinning techni-
ques can go down to the tens of micrometers or even nanoscale.
However, this process is limited by the presence of harsh solvents
required for 3D printing and poor control over architecture.46
Recently, the direct-write electrospinning technique has surfaced as an
alternative printing platform that allows the user to more precisely
control the individual strands similar to extrusion-based printing but at
the sub-micrometer scale.47,48
Latest developments in 3D printing also highlight printers (e.g.,
regenHU) capable of simultaneously producing both extrusion-based
and electrospun bioinks, giving researchers access to a broader range of
materials, printing conditions, and architecture for 3D printing.
Whereas thermoplastics can be cured simply by allowing the strands to
cool, hydrogels typically require an additional cross-linking process,
either chemical, photochemical, or thermal, to stabilize the resulting
structure. Consequently, the desired structure, architecture, and printing
strategy are highly dependent on the hydrogel of choice to be 3D
printed. Stereolithography-based printing is commonly used for hydro-
gels that require a light source (visible or UV) to cross-link to create
intricate structures using both naturally derived24,26,27 and synthetic25,49
materials with a high degree of spatial resolution. Polymer viscosity is
not a significant barrier in construct fabrication using this technology.
However, this platform is more conducive for single-material 3D print-
ing due to its use of a single polymer-containing vat. In contrast,
extrusion-based printing enables researchers to print more than one bio-
ink and often a mix of multiple polymers at a single time. The downside
is that specific rheological properties are required (such as thixotropy,
viscosity, storage, and loss modulus) to create a stable structure after
extrusion.31,50 Indeed, researchers have explored novel chemistries,51 gel-
in-gel printing,52,53 and polymerization strategies,54 to circumvent some
of these limitations. Although advantageous, the need for specialized
equipment, expensive materials, or highly specific protocols restricts
their broad application across 3DP platforms and target tissues.
3DP applications are further complicated by the presence of cells
and biologics in the system. To ensure cell viability and activity, the
permissible range of temperature, pressure, and cross-linking places
constraints on the printing process. For example, incorporation of cells
in stereolithography-based vat polymerization is often limited due to
the high volumes of polymer solution required and long UV exposure
times. Similarly, extrusion printing subjects cells to shear forces that
are detrimental to cell viability, making it challenging to print more
sensitive cells such as induced pluripotent stem cells (iPSCs) or other
stem cells that are easily damaged. Alternatively, inkjet and LIFT bio-
printing allow for the printing of polymer solutions with low viscosi-
ties and have been used to print a broad range of tissues.38,43 These
examples illustrate how the desired product may impact the selection
of a 3DP fabrication method, or, conversely, how limitation in the fab-
rication method can restrict tissue design.
Printing platforms have evolved significantly over the past few
years as the field of 3D printing has rapidly expanded. For example, to
counter the long print times (hours) associated with stereolitho-
graphic layer-by-layer printing, recent approaches have sought to
significantly speed up this process to seconds, potentially enabling
scale-up opportunities of biomanufacturing.55,56 Similarly, the integra-
tion of medical imaging data such as computed tomography (CT) and
magnetic resonance imaging (MRI) scans with existing 3D printing
platforms has further paved the way for personalized therapies that
utilize non-planar extrusion printing to fabricate complex 3D con-
structs.57,58 Other printing techniques such as digital micro-mirror
device (DMD) stereolithography,59 coaxial 3D printing,60,61 and
spheroid-based scaffold free fabrication62 have further pushed the
boundaries of 3D printing applications.
In parallel, a significant amount of research has been devoted to
the development of novel multi-material,63,64 and hybrid bioinks65
that are able to effectively capture the inherent biochemical and bio-
physical complexity of the native extracellular matrix. The incorpora-
tion of multiple materials will allow for these systems to exhibit
multiple behaviors.66 For instance, to make a bone mimetic, research-
ers have been utilizing a rigid support material such as thermoplastic
polymers in addition to an active, soft material such as a hydrogel bio-
ink to elicit the desired cellular response.58,67 However, the inherent
mismatch of material properties between these layers or regions leads
to poor scaffold performance and failures. Although our knowledge
base has progressed with these distinct interfaces, gradients may prove
more representative and mimetic of these niches where cells have spe-
cific functions in discrete environments. As such, the current trend of
looking at interfaces in 3D printing and tightly controlling these inter-
facial boundaries will prove to be a promising field of research as the
printed constructs grow in complexity and function.
The musculoskeletal system is a topic of great interest in interface
tissue engineering. It poses a very interesting challenge due to the rapid
variations in cellular, mechanical, and ECM composition in a very
short spatial range. 3D printing strategies for tissues such as carti-
lage,35,68 the osteochondral interface,6,69 and tendons70–72 have been
well explored to recapitulate their native complexities. As opposed to
gradient tissues, skin is a highly complex, stratified tissue that has been
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well studied in tissue engineering for over two decades. Current clini-
cal treatments for skin regeneration focus mainly on the epidermal
layer and are unable to capture the intricate neurovascular, follicular,
and sebaceous gland architecture of the dermal and hypodermal
layer.73 Consequently, 3D printing research has aggressively focused
on recreating these distinct, yet interconnected layers in order to pro-
vide more meaningful clinical treatments and therapies for patients
suffering from severe 2nd and 3rd degree injuries.
TABLE I. Comparison of common 3D printing methods. This table outlines key attributes for each of the common printing methods to aid in selecting the best fabrication strategy
for a given tissue engineering application.
Method Example materials
Typical
resolution Key attributes References
 Photocurable
resins/inks
50 lm Pros: high speed, well devel-
oped technology, low cost, and
no viscosity limitations
4, 23–27
Cons: still limited materials;
bioprinting is limited; multi-
material printing requires
changing out print resins
 Synthetic and natu-
ral polymers,
bioinks, and
decellularized ECM
100–200 lm Pros: moderate to low cost;
high cell density/viability; large
number of commercially avail-
able printers; and multiple
materials can be printed at
once
22, 30, 31
Cons: slow; need for viscous
materials; and viability can be
affected if shear stress is too
high
 Polymers;
thermoplastics
100–200 lm Pros: compatible with a large
range of biomaterials and com-
posites; low cost; and can be
used concurrently with 3D
bioplotting
32–37
Cons: slow; acellular due to
high temperature and pres-
sures; and cells need to be
seeded after fabrication
Synthetic and
natural polymers
10 lm Pros: high precision/accuracy;
can be used with multiple
materials and cell types; and
can be used to fabricate lab-on-
a-chip devices
38–40
Cons: high cost, long fabrica-
tion times; and potentially low
cell viability
Inkjet Synthetic and
natural polymers
10 lm to 100
lm
Pros: low cost; fast fabrication
times; and commercially avail-
able printers
41–43
Cons: poor integration between
layers and low cell density
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Apart from engineering functional tissues, 3D printing also serves
several niche applications such as drug delivery,74,75 temporal release
of drugs and biomolecules,76 and biomedical devices. The ability to
spatially pattern bioinks allows for the precise incorporation of the
desired drugs or biomolecules either on the surface or within the scaf-
fold, while controlling the material degradation rate allows us to con-
trol the dosage that ultimately diffuses out of the construct and enters
the body. This is in stark contrast to current production techniques for
most drugs, which rely on large-scale manufacturing, long production
times, and a one-size-fits-all approach. Indeed, with the first Food and
Drug Administration (FDA)-approved 3D printed drug Spritam in
2015, the field has opened up toward several drug encapsulation and
delivery applications for various tissues.77–79 The drug release profile is
undoubtedly a critical aspect of drug design and consequently its
approval procedure. For example, the active ingredient of Spritam
(1000mg of levetiracetam) disintegrates within seconds after taking a
sip of water.75 Personalized approaches allow for several potential
patient-centric advantages such as tailoring the drug dosage based on
age or anatomy, designing its release profile so they have to take pills
less frequently, or delivering extremely low or multi-drug doses that
combine multiple medications. Key attributes of the established FDA
regulatory pathway such as drug safety and efficacy, distribution and
metabolism of the active and inactive ingredients, and effects of drug
dosage over time can be readily translated to its 3DP counterparts. In
order to safely expedite the approval of novel 3DP therapies, several
as-yet unanswered aspects of drug design need to be integrated into
the established regulatory process for optimal results, such as role of
3DP geometry, material processing, impact of the 3DP technology
(powder bed vs extrusion vs stereolithography) on material parameters
and drug efficacy, feasibility of the traditional drug screening process
on state-of-the-art 3DP drug products, proper evaluation of personal-
ized doses for patients, and presence of any intermediate products dur-
ing the 3DP process.
FUTURE GOALS AND TRENDS FOR THE FIELD
Unlike traditional fabrication methods, 3D printing is still in its
infancy in terms of the regulations and guidelines for characterizing
these materials. As such, researchers typically rely on characterization
strategies and ASTM standards developed for other materials/
manufacturing techniques. However, more headway needs to be made
to establish standards and benchmarks for defining material printabil-
ity and testing 3D printed constructs and how these constructs are
analyzed from a materials perspective. This will help address several of
the major problems associated with 3D printing and its adaptation:
print fidelity, repeatability, and validation. Once addressed, this
manufacturing technique will move from niche applications to play a
more ubiquitous role in addressing biological questions and the
advancement of engineered tissues.
As the field develops, additional emphasis needs to be placed on
creating cell-specific niches where cell-substrate interactions can be
tightly controlled. The spatial control afforded by 3D printing will be
critical in modulating the cell substrate interactions as a function of
position. 3D printing and bioprinting can also be used with materials
that behave in a time-dependent manner, thereby allowing for tempo-
ral control of the mimetic environment and drug delivery on the req-
uisite time scale for modulating cellular functions.80–83 Spatial and
temporal control of the local microenvironment will be instrumental
in the development of complex, functional tissues where multiple
components need to work in concert to drive scaffold remodeling and
generate an active tissue. As with the other aspects of 3D printing that
are at the forefront of development, establishing clear and uniform
methods for assessing the functionality of time dependent materials is
critical for their widespread adoption.
With tissue-derived bioinks and decellularized ECM as the base
components of 3D printed scaffolds, additional questions will arise.
Although these materials are naturally derived, their source and process-
ing conditions may impact the presence and function of cell binding
motifs, growth factor binding and presentation, as well as potentially the
macroscopic presentation of fibers and their alignment within the printed
construct. The impact of these parameters could be substantial on the
advancement of these materials for tissue engineering applications.
Commercially available ECM materials such as Matrigel, gelatin,
and collagen have lot-to-lot and source dependent variability. The
same issues will impact in-house generated materials for 3D printing.
However, lot-to-lot variability will impact printability due to material
specifications such as the purity, contamination of salts or detergents
from the decellularization process, and the degree of substitution, for
materials where cross-linking is used to provide structural integrity.
Although there are standard protocols for the decellularization process
for multiple tissue types, there are many variations and these small
changes can impact the reproducibility of published work within and
between different research groups. To help alleviate these potential
issues, not only should the protocols followed be included in manu-
scripts, but we also suggest including supplemental information
regarding the purity (e.g., salt, detergent, DNA content, etc.) as well as
the range of degrees of substitution and molecular weights of the poly-
mers as needed to aid in the adoption of materials by other groups.
Journal policies for publication could play an important role in enforc-
ing these requirements.
There are a growing number of commercially available ECM-
derived materials for 3D printing, which have been fully characterized
from large scientific companies as well as smaller 3D printer start-up
companies. Biomaterial kits to be used in 3D printers are becoming
more widely available, and the validation for these materials can vary
from source-to-source. However, much like the materials developed
in-house, it will be critical for the same key parameters to be included
with each lot’s data sheet due to the impact that even a small perturba-
tion can have on printability. Modulating the material specifications to
enhance printability can have undesired consequences that need to be
fully understood when translating from in vitro to in vivo applications.
Although in vitro systems typically aim to mimic native tissues, trans-
lation will remain a significant challenge as the field matures. In partic-
ular, considerations need to be taken on how modification for sterility,
Good Manufacturing Practices (GMP) compliant materials/produc-
tion methods, and serum free conditions (recombinant protein and
defined culture conditions) can impact the performance of the mate-
rial as well as cellular response. When implanting in a patient, it is
critical to determine and, more importantly prevent any acute inflam-
matory response to the material, as well as monitor its long-term
effects. Consequently, it is often easier to obtain regulatory approval
for non-biological implants or for 3DP implants with pre-approved
materials. Other aspects of 3DP biological implants such as product
integrity after printing, maintaining biomanufacturing consistency
with regard to the cellular and biological properties, and sterility at
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every step of the manufacturing process must be considered. These
challenges can potentially create a bottleneck where additional regula-
tory hurdles need to be overcome for successful transition to the
industry/market to address patient needs.
Furthermore, there are different classes of medical devices (e.g.,
Classes I, II, and III for the FDA) that are regulated differently due to
the level of risk they pose to the patient and how much additional vali-
dation is required to ensure patient safety and device efficacy.84 For
3D printing and additive manufacturing, this adds a level of complex-
ity that needs to be accounted for prior to the fabrication of a new
therapeutic device. For instance, if one were to manufacture a Class I
device, which has the lowest degree of oversight, there are less strin-
gent guidelines to follow in the device fabrication process. Conversely,
a Class III device, such as an implant, would require the most stringent
guidelines to make it to market. There, each step of the manufacturing
process such as material selection, pre-processing, print parameters
(printer type, temperatures, resolution, orientation, etc.), and print
post-processing needs to be adequately controlled and verified to pro-
vide the best chance of meeting the FDA (or EU Medical Device
Regulation) requirements84,85 (Fig. 1). As we have discussed through-
out this text, we suggest that researchers publish these data in each
manuscript’s supplementary material section to provide a clear and
repeatable method of fabricating a device of interest. This is critical for
the long-term adoption of this technology for therapeutic use by main-
taining good records at each stage of the process.
A major advantage of 3D printing is the aspect of personalization.
The process of translating patient data into a printable product is well
established and optimized on the researchers’ side. Furthermore, the
use of FDA-approved materials for 3D printing and implantation
greatly expedites any clinical approvals required for the product to
come to the market. However, this represents a conundrum because
every patient is unique. Therefore, every stage of the 3D printing pro-
cess including raw material selection, pre-processing, the actual 3D
printing, post-processing, and sterilization prior to implantation have
inherent variations that are not necessarily subject to the same regula-
tory scrutiny (Fig. 1). In other words, the field has yet to address how a
scalable biomanufacturing technology that is also capable of individual-
ized treatments can pass important regulatory restrictions in a timely
manner. For instance, clinical trials have been carried out on a case-by-
case basis due to the regulatory hurdles in several countries using
patient-specific medical images to design the implant.84–86 The stand-
ards and benchmarks associated with 3D printing technologies and 3D
printed products, their quality assurance and control (QA/QC), and
criteria for success and failure are yet to be fully defined. These are
challenges that can only be addressed by the coordinated efforts of the
research, clinical, and industrial community. Specifically, as more indi-
vidual clinical trials are carried out with specific printers and materials,
the community needs to work toward developing standards that follow
similar production and post-processing procedures. Although the devi-
ces are patient-specific, it should be realized that the production meth-
ods can be generalized. As these opportunities arise, the community
needs to take advantage to facilitate a more timely transition from indi-
vidual exemptions to widespread clinical adoption and FDA approval.
One critical question also remains: how will these devices be fab-
ricated and/or mass produced? To meet all the necessary require-
ments, an extensive set of skills will be needed for each step in the
production process as described previously and outlined in Fig. 1. A
solution to this problem, which if not addressed would hinder and
potentially prevent the adoption of 3D printing by the medical com-
munity, would be to establish regional centers of excellence for print-
ing implants. Regional 3D printing centers would then develop (1) the
expertise needed, (2) the capacity required for the community, (3) the
regulatory practices necessary for approval, and (4) the distribution
networks to supply the surrounding region (100–500mile radius).
Centers of excellence would also be tasked with maintaining adequate
records for translation and could act as a repository from which
researchers could request information regarding successful material
treatments, processing conditions, and designs. Although individual
FIG 1. Key steps to generate clinically relevant 3D printed substrates. At each development and fabrication step, researchers need to aid in the development of standards as
well as evaluation and characterization methods to ensure repeatability. Consideration needs to be taken with the scale up of each of these steps when transitioning from small
scale laboratory settings to larger scale fabrication approaches. Additionally, hands on training and formal education regarding the different parameters that need to be con-
trolled as well as the limitations and constraints on different fabrication strategies will be critical for the continuous adoption of this technology as it matures.
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laboratories may be able to undertake a few of the above items, a cen-
ter devoted to this issue would provide an avenue to accelerate the
translational potential of 3D printed medical devices.
Finally, it is important to consider the best utility and application
of 3D printing in regenerative medicine. 3D printing is a fantastic
technology capable of recapitulating the biology, mechanics, and archi-
tecture of native tissue. It has seen its uses in possibly every organ,
including bone, skin, muscle, cartilage, heart, liver, kidney, and the
neural system. However, it is equally important to consider the com-
plexity associated with printing these structures, their feasibility, and
most importantly the value addition compared to standard casting or
alternative 3D fabrication methods. It is not uncommon to devote sig-
nificant time and resources toward 3D printing constructs that repre-
sent the desired mimic of the native system. Variations in bioinks,
printing protocols, and still-developing regulatory practices further
add to the complication. Therefore, it is necessary to ensure that the
3D printed construct represents a truly utilitarian advancement that
helps us answer, or pose, questions that would otherwise not be possi-
ble via traditional methods. Finally, the barriers to entry owing to the
high costs associated with printers, as well as recurring expenses, can
be prohibitively high. Indeed, with the recent rise in 3D printing start-
ups and an increasing number of 3D printers entering the market,
researchers and clinicians now have a broader range of affordable
options.
EDUCATION
To further aid in the adoption of this technology, education and
training are critical. Although there are some maker spaces for inventors
and individuals to have access to this technology, the accessibility of the
tools needed can be cost prohibitive. However, some groups and institu-
tions are attempting to address this issue through the use of open-
source 3D printers that can be built relatively inexpensively. At Carnegie
Mellon University (CMU), Dr. Adam Feinberg runs a short course
where researchers can come together and build their own open source
systems that utilize the Freeform Reversible Embedding of Suspended
Hydrogels (FRESH) technology.87 Others have taken similar approaches
to developing their own printers and have made these available to the
community. In addition, there is a cost associated with acquiring
patient-specific images for generating 3D models to test our printer
capabilities and fabricate patient specific models. Open source reposito-
ries such as the NIH 3D print exchange88 are one way of addressing this
need, but others should be developed to help augment this resource.
In additive manufacturing, the emphasis typically has been on
training graduate students either through research experiences or
through specific programs, such as the Master of Engineering
Program in Additive Manufacturing at the University of Maryland.
However, there is still a lack of programs for high school and under-
graduate education in additive manufacturing related to tissue engi-
neering problems. To address this issue, some institutions have begun
including 3D printers in their machine shops and libraries to encour-
age students and senior design/capstone teams to make use of this
technology. Typically, this does not provide a structured environment
for the students to learn more about this very dynamic field. We pro-
pose that additional courses and outreach activities need to be encour-
aged at a university level. For instance, Wake Forest Institute for
Regenerative Medicine (WFIRM) and Rice University have outreach
programs for high school students to give them hands on experience
to encourage them to become engineers in this ever-growing field. The
Summer Research Exposure Program (SREP) held by WFIRM is a 6-
week training course that pairs students with mentors, giving students
direct exposure to tissue engineering research. The Biomaterials Lab at
Rice University hosts a week-long internship program for high school
students over the summer interested in medicine and research.
Outreach alone will not be enough to address the increase in the
applicability of 3D printing to careers in biomedical engineering. As
more industry positions need experience with and exposure to 3D
printing technology, there will need to be a transition from mainly
graduate education (Professional degrees, masters, and Ph.D. level) to
undergraduate education. The programs being developed by universi-
ties along with commercial entities, such as Cellink and Allevi, to
enhance high school and undergraduate student education is critical
to fulfilling the need for more technically skilled workers in this grow-
ing field.
In practice, the medical community has been one of the first to
adopt this technology for training purposes. 3D printed models are
seeing use as a way to show medical students pathologies using life
size models that they may otherwise not see except as images during
their training.89–91 Models are not just limited to training but have
also been used by surgeons to help plan complex procedures.92,93
Training clinicians with 3D printed models and providing life-sized
models for surgical planning will improve patient care. As the medical
field becomes more familiar with this technology, it is expected that
additional strategies including additive manufacturing into patient
care will become more commonplace.
Adoption of this technology by industry partners is also key for
the long-term growth of this field. We foresee there being a shift at
institutional levels to meet the demand for more technically trained
students who have familiarity with 3D printing. In academia, tradi-
tionally, there has been an emphasis on basic and translational
research. However, as more institutions begin developing industry
partners, there may be a push for more translational research. There
has already been progress in this field in translating specific applica-
tions. For instance, high-throughput screening for efficacy and toxicity
of therapeutics, drugs, and materials can be made possible by 3D
printing strategies.94
To continue this trend and increase the success of translating
from the bench to commercial applications, the technical knowhow to
implement these strategies needs to become available to students
across all education levels. This in turn will lead to more career oppor-
tunities, and the familiarity with 3D printing technologies will provide
realistic expectations for what the technology can bring to the market.
Across all fields of tissue engineering currently implementing 3D
printing strategies, education will be key for its continuous adoption
and acceptance. A firm understanding of the current capabilities of
this technology will help drive the adoption of these techniques for
clinical and commercial applications.
CONCLUSIONS
3D bioprinting has seen rapid growth and widespread adoption
in recent years. As continuous progress is made in decreasing printer
cost and improving printing techniques, material availability, and
reproducibility, the adoption of additive manufacturing to more
diverse applications in tissue engineering will only continue to climb.
Bioinks, natural and artificial ECM based materials, and multi-
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material-based printing will lead the next generation advances in bio-
printing. However, these materials need to be fully characterized
beyond just printability to ensure reproducibility and enable their utili-
zation by others. Researchers should place an emphasis on guiding the
field toward developing standard techniques and aid in the adoption
of standards of regulatory agencies to provide a framework for clinical
translation. Establishing centers of 3D printing excellence would facili-
tate the transition from the bench to clinical applications by localizing
the expertise and minimizing the logistical problems that may plague
individual groups. In addition, educating the next generation of
researchers in the capabilities of this field will place a more realistic
expectation and understanding of how these various techniques can be
implemented. This will facilitate clear communication on the promise
of this technology and avoid over-hyping the technology as a conse-
quence of misunderstanding. As the field continues to mature,
addressing these barriers will enable the transition of 3D printing from
niche applications to a more widespread technique for 3D culture,
high-throughput screening, and device and implant fabrication.
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